- Home
- RAND vs TVRD Comparison
RAND vs TVRD Comparison
Compare RAND & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | TVRD |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 36.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAND | TVRD |
|---|---|---|
| Price | $10.90 | $3.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 3.5K | ★ 50.5K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $2.75 |
| 52 Week High | $21.30 | $43.65 |
Technical Indicators
Market Signals| Indicator | RAND | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 48.61 |
| Support Level | $10.53 | $2.75 |
| Resistance Level | $11.15 | $4.45 |
| Average True Range (ATR) | 0.31 | 0.21 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 19.46 | 74.29 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.